We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Ventana Paves the Way for High-Standard Companion Diagnostic Clinical Trials Services in China

By LabMedica International staff writers
Posted on 12 Aug 2014
Ventana Medical Systems, Inc. More...
(Tucson, AZ, USA), member of the Roche Group, has announced a new agreement with Quintiles, Inc. (Durham, NC, USA) to offer College of American Pathology (CAP)-standard companion diagnostic testing services to cancer patients in China via early phase clinical trials conducted by pharmaceutical and biotech companies. This is good news for patients as China is one of the only countries in the world that requires all patient samples be tested in China, even those used in clinical trials. And incorporating a companion diagnostic strategy into a drug development program is more likely to help develop more effective drugs with improved safety profiles for patients.

"Our new relationship with Quintiles to offer companion diagnostic testing services in China moves our mission, to improve the lives of all patients afflicted with cancer, a big step forward," said Doug Ward, vice president and Companion Diagnostics Lifecycle leader, Ventana, "Our oncology pharma collaborators can now reach a large and growing number of patients that can benefit from clinical trial participation using targeted treatments and tests."

According to the World Health Organization (WHO)'s latest World Cancer Report, in 2012 China had the highest rate of new cancer cases recorded globally, 3.07 million (21.9%), and the trend is increasing, particularly in lung, liver, esophageal, and stomach cancers. This underscores the growing need for patients in China to have in-country access to the most advanced tissue diagnostic testing and companion therapeutics in the industry, which starts with early phase clinical trials.

"It's been extremely important to Ventana that we find a strategic laboratory in China that will help us uphold the CAP testing standard of excellence set by our global companion diagnostic CAP/CLIA laboratory in Tucson, Arizona, USA," said Dr. H. James Hnatyszyn, Ventana director of Laboratory Operations for companion diagnostics, "Quintiles has the experience, infrastructure, and qualified personnel to meet this challenge."

Early phase clinical trial testing according to the rigorous CAP standards set by Ventana is now available.

Related Links:
Ventana Medical Systems
Quintiles



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Manual Pipetting Aid
Pipette Controllers macro
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.